Checkpoint Inhibition Prior to Stem Cell Transplantation Increases the Risk of Inflammatory Adverse Events

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing Interests

Malek Shatila, Antonio Pizuorno Machado, Jay Shah, Andres Urias Rivera, Sidra Naz, Stephen Glombicki, Sharada Wali, Eric Lu, Nicholas Short, Anusha Thomas, Hao Chi Zhang, and Yinghong Wang declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

Ethics Approval and Consent to Participate

The ethics approval for this study was granted by the institutional review board at The University of Texas MD Anderson Cancer Center (PA18-0472). Patient consent was waived for this study.

Consent to Publish

Not applicable.

Data Availability

The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Code Availability

Not applicable.

Author Contributions

Yinghong Wang, who was the senior author of this article, developed the concept, designed the study, interpreted the results, ensured the preservation of data accuracy and integrity at all stages, agreed to be accountable for all aspects of the study, was in charge of the overall direction and planning of the study, and contributed to the writing of the manuscript, with input from all authors. Malek Shatila conceptualized and designed the study, collected the data, conducted the analyses and drafted the manuscript. Eric Lu assisted with drafting the manuscript. Antonio Pizuorno Machado, Jay Shah, Andres Urias Rivera, Stephen Glombicki, and Sidra Naz assisted with data collection. Sharada Wali added new data and ran new analysis for revision. All the authors critically revised the final version of the manuscript and approved the final manuscript.

Comments (0)

No login
gif